Immuno-Biological Laboratories Co., Ltd. (4570.T)
JPY 449.0
(2.05%)
JPY 449.0
(2.05%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 186.69 Million JPY | 164.44% |
| 2022 | -289.73 Million JPY | -11.97% |
| 2021 | -258.76 Million JPY | 18.84% |
| 2020 | -318.82 Million JPY | 52.27% |
| 2019 | -668 Million JPY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 51 Million JPY | -69.3% |
| 2023 Q3 | -6.27 Million JPY | -139.97% |
| 2023 Q1 | 11.16 Million JPY | 105.23% |
| 2023 Q4 | 166.1 Million JPY | 2747.95% |
| 2023 FY | 186.69 Million JPY | 164.44% |
| 2023 Q2 | 15.69 Million JPY | 40.58% |
| 2022 Q3 | 59.73 Million JPY | 177.35% |
| 2022 FY | -289.73 Million JPY | -11.97% |
| 2022 Q4 | -213.3 Million JPY | -457.06% |
| 2022 Q2 | -77.23 Million JPY | 0.0% |
| 2021 FY | -258.76 Million JPY | 18.84% |
| 2020 FY | -318.82 Million JPY | 52.27% |
| 2019 FY | -668 Million JPY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 384 Million JPY | 51.382% |
| PRISM BioLab Co.,LTD | -526.91 Million JPY | 135.432% |
| GNI Group Ltd. | 8.09 Billion JPY | 97.693% |
| Linical Co., Ltd. | 338.26 Million JPY | 44.809% |
| Trans Genic Inc. | 4.08 Million JPY | -4470.233% |
| MEDINET Co., Ltd. | -1.43 Billion JPY | 112.983% |
| Soiken Holdings Inc. | -662.2 Million JPY | 128.193% |
| Cytori Cell Research Institute, Inc. | 138.15 Million JPY | -35.134% |
| AnGes, Inc. | -7.43 Billion JPY | 102.51% |
| OncoTherapy Science, Inc. | -1.28 Billion JPY | 114.493% |
| Nxera Pharma Co., Ltd. | -7.19 Billion JPY | 102.595% |
| NanoCarrier Co., Ltd. | -780 Million JPY | 123.935% |
| Carna Biosciences, Inc. | -1.15 Billion JPY | 116.193% |
| CanBas Co., Ltd. | -1.2 Billion JPY | 115.442% |
| D. Western Therapeutics Institute, Inc. | -812.41 Million JPY | 122.98% |
| RaQualia Pharma Inc. | -323.66 Million JPY | 157.682% |
| Chiome Bioscience Inc. | -1.22 Billion JPY | 115.303% |
| Kidswell Bio Corporation | -1.42 Billion JPY | 113.128% |
| PeptiDream Inc. | 3.03 Billion JPY | 93.85% |
| Oncolys BioPharma Inc. | -1.93 Billion JPY | 109.631% |
| Ribomic Inc. | -1.02 Billion JPY | 118.228% |
| SanBio Company Limited | -2.64 Billion JPY | 107.061% |
| Healios K.K. | -3.82 Billion JPY | 104.883% |
| BrightPath Biotherapeutics Co., Ltd. | -1.16 Billion JPY | 115.983% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -1.48 Billion JPY | 112.533% |
| Delta-Fly Pharma, Inc. | -1.42 Billion JPY | 113.061% |
| StemRIM | -2.02 Billion JPY | 109.233% |
| CellSource Co., Ltd. | 923.14 Million JPY | 79.776% |
| FunPep Company Limited | -933.41 Million JPY | 120.001% |
| Kringle Pharma, Inc. | -854.15 Million JPY | 121.857% |
| Stella Pharma Corporation | -763.74 Million JPY | 124.444% |
| TMS Co., Ltd. | -960.04 Million JPY | 119.446% |
| Noile-Immune Biotech Inc. | -1.13 Billion JPY | 116.521% |
| Cuorips Inc. | -632.18 Million JPY | 129.532% |
| K Pharma,Inc. | 260.33 Million JPY | 28.286% |
| Takara Bio Inc. | 1.48 Billion JPY | 87.386% |
| ReproCELL Incorporated | -31.41 Million JPY | 694.283% |
| PhoenixBio Co., Ltd. | 26.37 Million JPY | -607.764% |
| StemCell Institute Inc. | 310.98 Million JPY | 39.966% |
| Japan Tissue Engineering Co., Ltd. | 143.16 Million JPY | -30.401% |
| CellSeed Inc. | -846.53 Million JPY | 122.054% |